Skip to main content

Main menu

  • Home
  • Current issue
  • ERJ Early View
  • Past issues
  • Authors/reviewers
    • Instructions for authors
    • Submit a manuscript
    • Open access
    • COVID-19 submission information
    • Peer reviewer login
  • Alerts
  • Podcasts
  • Subscriptions
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

User menu

  • Log in
  • Subscribe
  • Contact Us
  • My Cart

Search

  • Advanced search
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

Login

European Respiratory Society

Advanced Search

  • Home
  • Current issue
  • ERJ Early View
  • Past issues
  • Authors/reviewers
    • Instructions for authors
    • Submit a manuscript
    • Open access
    • COVID-19 submission information
    • Peer reviewer login
  • Alerts
  • Podcasts
  • Subscriptions

Dupilumab improves asthma control and quality of life in children with uncontrolled persistent asthma

Alessandro Fiocchi, Wanda Phipatanakul, Sandy R. Durrani, Jeremy Cole, Xuezhou Mao, Jérôme Msihid, David J. Lederer, Megan Hardin, Yi Zhang, Asif H. Khan
European Respiratory Journal 2021 58: PA3920; DOI: 10.1183/13993003.congress-2021.PA3920
Alessandro Fiocchi
1Bambino Gesù Children’s Hospital IRCCS, Rome, Italy
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: Alessandro.fiocchi@allegriallergia.net
Wanda Phipatanakul
2Boston Children’s Hospital, Harvard Medical School, Boston, United States of America
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Sandy R. Durrani
3Cincinnati Children’s Hospital Medical Center, University of Cincinnati College of Medicine, Cincinnati, United States of America
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jeremy Cole
4OK Clinical Research, Edmund, United States of America
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Xuezhou Mao
5Sanofi, Bridgewater, United States of America
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jérôme Msihid
6Sanofi, Chilly-Mazarin, France
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
David J. Lederer
7Regeneron Pharmaceuticals, Inc., Tarrytown, United States of America
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Megan Hardin
8Sanofi, Cambridge, United States of America
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Yi Zhang
7Regeneron Pharmaceuticals, Inc., Tarrytown, United States of America
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Asif H. Khan
6Sanofi, Chilly-Mazarin, France
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
Loading

Abstract

Background: Asthma is the most common chronic respiratory condition in children, who may have uncontrolled disease despite maximal therapy. Type 2 (T2) inflammation (blood eosinophils ≥150 cells/µL or FeNO ≥20 ppb) underlies most pediatric asthma. Dupilumab (DPL), a fully human mAb, blocks the shared receptor component for IL-4/13, key and central drivers of T2 inflammation. VOYAGE, a 52-week randomized, double-blind, placebo (PBO)-controlled phase 3 study (NCT02948959), evaluated DPL efficacy/safety in children aged 6–11 years with uncontrolled persistent asthma.

Aim: Assess DPL impact on asthma control (ACQ-7-IA) and health-related quality of life (HRQoL; PAQLQ[S]-IA) in VOYAGE T2 patients (pts).

Methods: Change from baseline in ACQ-7-IA/PAQLQ[S]-IA scores, percentage of responders (improvement ≥0.5) or pts who achieved well-controlled asthma (ACQ-7-IA score ≤0.75).

Results: DPL vs PBO rapidly improved asthma control by Week (Wk)4 and was sustained to Wk52 (P<0.05). At Wk24, 79% DPL vs 69% PBO pts were ACQ-7-IA responders and 61% DPL vs 43% PBO achieved well-controlled asthma (P<0.05). From Wk36, DPL vs PBO significantly improved PAQLQ[S]-IA scores across all domains—symptoms, activity limitation, emotional. A higher proportion of DPL vs PBO pts were PAQLQ[S]-IA responders at Wk52 (P<0.05; Figure).

Conclusion: In children with uncontrolled T2 asthma, DPL rapidly improved asthma control. HRQoL also improved over time.

Figure
  • Download figure
  • Open in new tab
  • Download powerpoint
  • Children
  • Quality of life
  • Asthma - management

Footnotes

Cite this article as: European Respiratory Journal 2021; 58: Suppl. 65, PA3920.

This abstract was presented at the 2021 ERS International Congress, in session “Prediction of exacerbations in patients with COPD”.

This is an ERS International Congress abstract. No full-text version is available. Further material to accompany this abstract may be available at www.ers-education.org (ERS member access only).

  • Copyright ©the authors 2021
Previous
Back to top
Vol 58 Issue suppl 65 Table of Contents
  • Table of Contents
  • Index by author
Email

Thank you for your interest in spreading the word on European Respiratory Society .

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Dupilumab improves asthma control and quality of life in children with uncontrolled persistent asthma
(Your Name) has sent you a message from European Respiratory Society
(Your Name) thought you would like to see the European Respiratory Society web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Dupilumab improves asthma control and quality of life in children with uncontrolled persistent asthma
Alessandro Fiocchi, Wanda Phipatanakul, Sandy R. Durrani, Jeremy Cole, Xuezhou Mao, Jérôme Msihid, David J. Lederer, Megan Hardin, Yi Zhang, Asif H. Khan
European Respiratory Journal Sep 2021, 58 (suppl 65) PA3920; DOI: 10.1183/13993003.congress-2021.PA3920

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

Share
Dupilumab improves asthma control and quality of life in children with uncontrolled persistent asthma
Alessandro Fiocchi, Wanda Phipatanakul, Sandy R. Durrani, Jeremy Cole, Xuezhou Mao, Jérôme Msihid, David J. Lederer, Megan Hardin, Yi Zhang, Asif H. Khan
European Respiratory Journal Sep 2021, 58 (suppl 65) PA3920; DOI: 10.1183/13993003.congress-2021.PA3920
del.icio.us logo Digg logo Reddit logo Technorati logo Twitter logo CiteULike logo Connotea logo Facebook logo Google logo Mendeley logo

Jump To

  • Article
  • Figures & Data
  • Info & Metrics
  • Tweet Widget
  • Facebook Like
  • Google Plus One

More in this TOC Section

  • Monoclonal antibody treatments for paediatric severe asthma–outcomes, attitudes and adherence
  • A systematic review of the proportion of adolescents recruited to RCTs of asthma treatments for adults and adolescents
  • Impact of COVID-19 side-effects on pediatric and adult patients with recurrent wheeze and asthma
Show more Paediatric asthma and allergy

Related Articles

Navigate

  • Home
  • Current issue
  • Archive

About the ERJ

  • Journal information
  • Editorial board
  • Reviewers
  • Press
  • Permissions and reprints
  • Advertising

The European Respiratory Society

  • Society home
  • myERS
  • Privacy policy
  • Accessibility

ERS publications

  • European Respiratory Journal
  • ERJ Open Research
  • European Respiratory Review
  • Breathe
  • ERS books online
  • ERS Bookshop

Help

  • Feedback

For authors

  • Instructions for authors
  • Publication ethics and malpractice
  • Submit a manuscript

For readers

  • Alerts
  • Subjects
  • Podcasts
  • RSS

Subscriptions

  • Accessing the ERS publications

Contact us

European Respiratory Society
442 Glossop Road
Sheffield S10 2PX
United Kingdom
Tel: +44 114 2672860
Email: journals@ersnet.org

ISSN

Print ISSN:  0903-1936
Online ISSN: 1399-3003

Copyright © 2023 by the European Respiratory Society